Multiple Myeloma in the Time of COVID-19.

"Disclosure Statement The authors have no conflicts of interest to declare related to this paper. A.S.A.: no conflicts of interest to declare. T.S.: advisory board: Akcea, Alnylam, and Astrazeneca. Research support: InCyte and Prothena. M.A.G.: personal fees: Ionis/Akcea, Alnylam, Prothena, Celgene, Janssen, Spectrum, Annexon, Appellis, Research to Practice, Amgen, Medscape, Physicians Education Resource, and Abbvie. Grants: Spectrum, Amyloidosis Foundation, and International Waldenstrom Foundation. Speaker fees: Teva, Johnson and Johnson, Medscape, and DAVA oncology. Advisory board: Pharmacyclics and Proclara. Royalties: Springer Publishing. Development of educational material: i3Health. Stock options: Aurora Bio."

"Funding Sources The authors have no funding sources to declare."